Novartis drug Votubia® receives EU approval to treat refractory partial-onset seizures in patients with TSC Approval addresses unmet need as up to 60% of patients with TSC suffering from seizures become unresponsive to available anti-epileptic therapies[1] Decision marks the third TSC-related indication for Votubia in the EU, where it [..]
New Sensors to Detect Single Protein Molecules: MIT Research By: Anne Trafton | MIT News Office January 26, 2017 For the first time, MIT engineers have designed sensors that can detect single protein molecules as they are secreted by cells or even a single cell. These sensors, which consist of chemically [..]
Pilot Program Started by NIH for Innovative Neurological Research By: NIH News January 26, 2017 The first 30 recipients of the new R35 Research Program Award (RPA), a pilot program designed to encourage creative research by enhancing funding stability, have been announced by the National Institute of Neurological Disorders and Stroke [..]
Study: Technological Progress Alone Won’t Stem Resource Use Jennifer Chu | MIT News Office January 24, 2017 Are humans taking more resources from the Earth than the planet can safely produce? The answer lies partly in whether we can “dematerialize,” or reduce the amount of materials needed to produce goods [..]
Kripa Varanasi: Innovating at Interfaces David L. Chandler | MIT News Office January 24, 2017 Ketchup’s sluggish pace as it oozes out of its bottle is a longstanding nuisance — but one that is about to be upended by a new product coming to market. The brainchild of MIT mechanical [..]
FDA Grants Priority Review For Genentech’s Actemra® (Tocilizumab) For Giant Cell Arteritis There have been no new therapies for GCA in more than 50 years Breakthrough Therapy Designation was granted to Actemra for the treatment of GCA by the FDA in 2016 January 24, 2017 Genentech, a member of the [..]
GPS For Tracking Immune Cells as They Hunt for Tumors By: JENNIE DUSHECK, Stanford News January 23, 2017 A study led by researchers at the Stanford University School of Medicine has for the first time demonstrated a way to visualize and monitor the behavior of immune cells used to treat cancer patients. The [..]
Toxic Brain Cells May Caues Many Neurodegenerative Diseases By: BRUCE GOLDMAN; Stanford News January 23, 2017 While most of us haven’t heard of astrocytes, these cells are four times as plentiful in the human brain as nerve cells. Now, a team led by researchers at the Stanford University School of Medicine has [..]
BIRAC Announces 10th Call for Proposals under the Biotechnology Ignition Grant (BIG) Scheme 1st Jan-15th Feb, 2017 Biotechnology Industry Research Assistance Council (BIRAC), a Section 8 ‘Not-for-Profit Company’ of Government of India, has been set up as DBT’s interface agency, to serve as a single window for emerging biotech companies. [..]
Wearable Biosensors Can Tell When You Are Getting Sick By: JENNIE DUSHECK : Stanford News January 20, 2017 New research from Stanford shows that fitness monitors and other wearable biosensors can tell when an individual’s heart rate, skin temperature and other measures are abnormal, suggesting possible illness. Wearable sensors that monitor heart [..]
NIH Launched a New Drug Formulary For Expedite Use of Agents in Clinical Trials By: NIH News January 20, 2017 The National Cancer Institute (NCI) today launched a new drug formulary (the “NCI Formulary”) that will enable investigators at NCI-designated Cancer Centers to have quicker access to approved and investigational [..]
FDA approval to Trulance of Synergy Pharmaceuticals : for Chronic Idiopathic Constipation By: News Synergy Pharmaceuticals January 20, 2017 Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the U.S. Food and Drug Administration (FDA) has approved TRULANCE™ (plecanatide) for the treatment of adults with chronic idiopathic constipation (CIC). TRULANCE is the first drug designed [..]
FDA grants Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) Priority Review in additional type of advanced bladder cancer TECENTRIQ being evaluated as first-line treatment option for people not eligible for cisplatin chemotherapy Second Priority Review granted for TECENTRIQ in advanced bladder cancer From Roche News 18 January 2017 Roche (SIX: RO, ROG; [..]
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) for Myopic Choroidal Neovascularization Myopic CNV is a complication of severe near-sightedness and most commonly affects people between ages 45 and 64 Granted Priority Review by the FDA Fifth FDA-approved indication for Lucentis since its launch in 2006 By: Genentech News January 18, 2017 [..]
New Powerful Method Towards The Development of Kinase Inhibitors Eric Bender | MIT Industrial Liaison Program January 18, 2017 “Kinase inhibitor” drugs, which target a class of enzymes that are crucial to keep cells running, make up one of the great success stories of modern medicine. “When kinase proteins go wrong, [..]
A Step Toward Renewable Diesel By: Anne Trafton | MIT News Office January 18, 2017 MIT engineers have genetically reprogrammed a strain of yeast so that it converts sugars to fats much more efficiently, an advance that could make possible the renewable production of high-energy fuels such as diesel. The [..]
A 20-cent, Hand-Powered Blood Centrifuge: Inspired by a Whirligig Toy January 10 2017 By: Kris Newby (Stanford News) Here’s how to build a whirligig: Thread a loop of twine through two holes in a button. Grab the loop ends, then rhythmically pull. As the twine coils and uncoils, the button spins at [..]
Some Catalysts Contribute Their Own Oxygen For Reactions By: David L. Chandler | MIT News Office January 10, 2017 Chemical reactions that release oxygen in the presence of a catalyst, known as oxygen-evolution reactions, are a crucial part of chemical energy storage processes, including water splitting, electrochemical carbon dioxide reduction, [..]
Novartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders Novartis enters into an exclusive option agreement with Ionis and Akcea to license two investigational treatments expected to significantly reduce cardiovascular risk in patients living with elevated levels of lipoprotein Lp(a) or ApoCIII, which [..]
Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for PF-06410293, a Potential Biosimilar to Humira®1 (adalimumab) January 9, 2017 Pfizer Inc. (NYSE:PFE) announced that the comparative, confirmatory REFLECTIONS B538-02 study met its primary objective by demonstrating equivalent efficacy as measured by the American College of Rheumatology 20 [..]
New Computational Model to Understand Inhibitory Neurons By: Larry Hardesty | MIT News Office January 9, 2017 Researchers at MIT’s Computer Science and Artificial Intelligence Laboratory have developed a new computational model of a neural circuit in the brain, which could shed light on the biological role of inhibitory neurons [..]
Strongest And Lightest Material Discovered by MIT Scientists By: David L. Chandler | MIT News Office January 9, 2017 A team of researchers at MIT has designed one of the strongest lightweight materials known, by compressing and fusing flakes of graphene, a two-dimensional form of carbon. The new material, a [..]
Three Atom Wide Electrical Wire Using World’s Smallest Diamonds January 4, 2017 By: Menlo Park (Stanford News) Scientists at Stanford University and the Department of Energy’s SLAC National Accelerator Laboratory have discovered a way to use diamondoids – the smallest possible bits of diamond – to assemble atoms into the thinnest [..]
New Way to Test Biological Force Sensor Technology : With Nanopartical Eating Worms By Taylor Kubota (Stanfor NEWS) January 4, 2017 Millimeter-long worms digesting a nanoparticle-laced meal of their favorite bacteria could eventually lead to a new way to see cellular forces at play within our own bodies, including processes like [..]
More Sensitive 3-D antibody Arrays : Useful for Disease Diagnosis By: Anne Trafton | MIT News Office January 4, 2017 Exploiting a process known as molecular self-assembly, MIT chemical engineers have built three-dimensional arrays of antibodies that could be used as sensors to diagnose diseases such as malaria or tuberculosis. [..]
First Drug for Spinal Muscular Atrophy, SPINRAZA™ (nusinersen), Approved by FDA January 1, 2017 The U.S. Food and Drug Administration (FDA) approved Biogen’s (NASDAQ: BIIB) SPINRAZA™ (nusinersen) under Priority Review for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. SPINRAZA is the first and only treatment approved in [..]
New Oral Drug, Selumetinib Demonstrates Shrinkage in Pediatric Neural Tumors in Early-Phase Trial January 1, 2017 By: NIH News In an early-phase clinical trial of a new oral drug, selumetinib, children with the common genetic disorder neurofibromatosis type 1 (NF1) and plexiform neurofibromas, tumors of the peripheral nerves, tolerated selumetinib and, [..]
Copyright © 2024 | WordPress Theme by MH Themes